ClinicalTrials.gg
CompletedNCT05245578Updated Feb 18, 2022

Safety Evaluation of KX01 Ointment 1% in Japanese Healthy Male Subjects

A Phase 1 interventional study of KX01 ointment 1% and Placebo ointment in Healthy Volunteer, sponsored by PharmaEssentia. Completed at 1 site in Japan. Open to male participants aged 20 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-18.

Sponsored by PharmaEssentia · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
20 Years to 65 Years
Sex
Male
01

Study summary

Skin Irritation and Phototoxicity Study of KX01 Ointment 1% in Japanese healthy male subjects

Read the detailed description

A baseline evaluation of the patch sites will be performed immediately prior to application of the patches to ensure that no conditions, markings, or coloration of the skin will interfere with interpretation of the study results.

A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01KX2-391 ointment 1% and 2 sites for Placebo vehicle ointment. One set (KX01 ointment 1% IP and Placebo ointment vehicle patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions. The distance between the patches will be no less than one centimeter.

The numbering of the test sites will remain the same throughout the study. The sites will be marked with an indelible, surgical marker.

02

Conditions studied

  • Healthy Volunteer

Browse trials for

Keywords

  • Skin Irritation
  • Phototoxicity
03

In context

Dermatitis, Phototoxic

11 studies on the registry are indexed under Dermatitis, Phototoxic; none are open to participants now.

This study's enrollment of 20 is below the median of 37 across 10 interventional studies indexed under Dermatitis, Phototoxic.

Browse Dermatitis, Phototoxic studies →

Lead sponsor

PharmaEssentia is the lead sponsor of 17 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Japanese male adult, whose age 20-65 years old

Exclusion criteria

Exclusion Criteria:

  • History of photosensitivity or photoallergy
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    KX01 ointment and Placebo ointment

    Drug: KX01 ointment 1% · Drug: Placebo ointment

Interventions

  • A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.

  • DrugPlacebo ointment

    A total of 4 application sites (2 cm x 2 cm each) will be marked on each subject's back, placing 2 sites for KX01 ointment 1% and 2 sites for Placebo ointment. One set (KX01 ointment 1% and Placebo ointment patches) will be designated for irradiation and the other set will remain non-irradiated under open conditions.

06

What researchers measure

Primary outcomes

  1. Degree of skin irritation at application site

    Degree of skin irritation will be evaluated according to the criteria (response scores and response notations). The same evaluator, if possible, should perform the assessment throughout the study.

    Time frame: 9 days

  2. Phototoxic potential at application site

    Phototoxic potential will be evaluated according to the criteria (response scores and response notations). The same evaluator, if possible, should perform the assessment throughout the study.

    Time frame: 9 days

Secondary outcomes

  1. Number of participants with adverse events as a measure of safety

    Time frame: 9 days

07

Study locations

1 site
  • Medical Corporation HOUEIKAI, Sekino Clinical Pharmacology Clinic
    Toshima-ku, Tokyo 171-0014, Japan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Nov 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2021
First posted
Feb 18, 2022
StartActual
Nov 16, 2021
Primary completionActual
Nov 22, 2021
CompletionActual
Jan 12, 2022
Last update
Feb 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05245578
Lead sponsor
PharmaEssentia
Collaborators
PharmaEssentia Japan K.K.
Responsible party
Sponsor
First posted
Feb 18, 2022
Start date
Nov 16, 2021
Primary completion
Nov 22, 2021
Completion
Jan 12, 2022
Last update
Feb 18, 2022

Study contacts

Hisakuni Sekino
principal investigator · Medical Corporation HOUEIKAI, Sekino Clinical Pharmacology Clinic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirbanibulin

Start the discussion